Get the latest Science News and Discoveries

Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions - EurekAlert


Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver transplantation, hepatectomy, and local ablation. However, the recurrence rate of HCC following hepatectomy or ablation remains alarmingly high, up to 70%, severely impacting patient prognosis and overall survival (OS). To mitigate postoperative recurrence and improve patient outcomes, various adjuvant therapies have been explored. Despite the efficacy of several adjuvant treatments in reducing recurrence rates and enhancing survival, there is no standardized consensus on their application across national guidelines, leading to significant disparities in recommendations between Eastern and Western medical practices.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of EurekAlert

EurekAlert

Photo of unanswered questions

unanswered questions

Photo of curative treatment

curative treatment

Related news:

News photo

Comparison of FDG-PET/CT and CT for treatment - EurekAlert

News photo

Oil and natural gas development in Permian is a key source of ozone pollution in Carlsbad Caverns National Park - EurekAlert

News photo

Digital dog and cat skull database - EurekAlert